Angiotensin converting enzyme inhibitor to angiotensin receptor blocker conversion
Pro Research Analysisby 
Searched over 200M research papers
Comparative Efficacy of ACE Inhibitors and ARBs in Hypertension and Cardiovascular Outcomes
Angiotensin-converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) are both widely used to manage hypertension and reduce cardiovascular risk. Research shows that both drug classes are similarly effective in lowering blood pressure and preventing major cardiovascular events such as myocardial infarction, stroke, and heart failure hospitalizations in patients with essential hypertension 235. However, some differences in outcomes have been observed.
Mortality and Cardiovascular Death: ACE Inhibitors vs. ARBs
Several studies indicate that ACE inhibitors may offer greater protection against total mortality and cardiovascular death compared to ARBs. Meta-analyses have found that while both drug classes are effective in reducing the risk of acute myocardial infarction, stroke, and heart failure hospitalizations, only ACE inhibitors significantly reduce total deaths and cardiovascular deaths . ARBs did not show a significant reduction in these outcomes compared to placebo or ACE inhibitors . Another large-scale analysis found no significant difference between ACE inhibitors and ARBs for myocardial infarction, cardiovascular mortality, or total mortality, but did note a slight trend toward lower stroke risk with ARBs .
Heart Failure and Hospitalization
Both ACE inhibitors and ARBs are effective in reducing the risk of heart failure and related hospitalizations, but ACE inhibitors may be more protective in preventing the progression of heart failure or the need for hospitalization in hypertensive patients .
Acute Myocardial Infarction: Post-Event Outcomes
In patients with acute myocardial infarction (AMI) and hypertension, ACE inhibitors appear to be superior to ARBs in reducing the risk of cardiac death, all-cause death, and recurrent myocardial infarction over a two-year period . This suggests that ACE inhibitors may be the preferred choice for blood pressure control in hypertensive patients following an AMI .
Clinical Considerations for Switching from ACE Inhibitors to ARBs
Switching from an ACE inhibitor to an ARB is often considered in patients who experience side effects such as cough or angioedema with ACE inhibitors. Both drug classes provide similar antihypertensive effects and are mildly cardioprotective, increasing survival in patients with heart failure and hypertension 16. The choice between the two may depend on individual patient tolerance and specific clinical scenarios.
Benefits in Normotensive and Atherosclerotic Patients
Both ACE inhibitors and ARBs are beneficial in patients with or at risk for atherosclerotic vascular disease, even in those who are normotensive. These medications reduce the risk of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, regardless of baseline blood pressure .
Conclusion
ACE inhibitors and ARBs are both effective for managing hypertension and reducing cardiovascular risk. ACE inhibitors may provide additional benefits in reducing total and cardiovascular mortality, especially in patients with a history of myocardial infarction or heart failure. ARBs are a suitable alternative for patients who cannot tolerate ACE inhibitors, with similar efficacy in most cardiovascular outcomes. The decision to switch from an ACE inhibitor to an ARB should be individualized based on patient-specific factors and side effect profiles 2359.
Sources and full results
Most relevant research papers on this topic